Movement Disorders

Here's some of what is coming soon to NeurologyLive® this week.

Over a 12-week treatment period, patients with Parkinson disease on light therapy demonstrated statistically significant improvements of 58% and 40% in lower and upper limb coordination and movement.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 24, 2023.

The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals provided perspective on the negative effects seen from quetiapine and how the knowledge of pimavanserin has improved since approval. [WATCH TIME: 5 minutes]

If approved, ABBV-951 will become the first subcutaneous delivery of carbidopa/levodopa, often considered the standard of care for symptom management for patients with Parkinson disease.

The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals discussed the ongoing challenges with lowering mortality in Parkinson disease, and the need to improve caregiver burden. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Patients with cerebellar ataxia made riskier decisions than controls, suggesting this may be a unique cerebellar cognitive symptom.

Neurology News Network for the week ending March 18, 2023. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

Expert neurologist highlights ongoing research in newer mechanisms of action and modes of delivery for treatments of Parkinson’s disease and OFF episodes.

Stuart Isaacson, MD, FAAN, evaluates the current treatment paradigm and highlights new, ‘on-demand’ medication for management of OFF episodes in Parkinson’s disease.

Stuart Isaacson, MD, FAAN, discusses the pharmacological basis of OFF episodes in patients with Parkinson’s disease.

In honor of Brain Awareness Week, held March 13, 2023, to March 19, 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

The vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals provided perspective on the mechanistic advantages of pimavanserin over atypical antipsychotics to treat Parkinson disease psychosis. [WATCH TIME: 2 minutes]

Frailty domains such as exhaustion, slow gait speed, low grip strength, and low physical activity were all associated with incident Parkinson disease.

The director of functional neurosurgery at Baptist Health Miami Neuroscience Institute provided perspective on the growth of high intensity focused ultrasound and the lessons learned when treating essential tremor.

In honor of Brain Awareness Week, a group of experts in the care of patients with neurological conditions—Ronald C. Petersen, MD, PhD; Brian Grosberg, MD, FAHS; James Beck, PhD; Michael Levy, MD, PhD; Stanley H. Appel, MD —shared their perspectives on hot topics of treatment and management in neurology.

Findings showed that global cognition declines in the prediagnostic period in men but not women with incident Parkinson disease, further indicating cognitive heterogeneity in the prodromal period by sex.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders.

Early data has shown a substantial neuroprotective benefit in response to c-Abl inhibition by IkT-148009.

Literature reveals an inconsistency in sex differences between women and men, among individuals living with dementia with Lewy bodies and their caregivers.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 10, 2023.

Expert neurologist reviews manifestations of OFF episodes and their impact on the quality of life of patients with Parkinson’s Disease.